Lesson plan
Aprocitentan
Aprocitentan, sold under the brand name Tryvio, is a medication used to treat hypertension (high blood pressure). It is developed by Idorsia. It is taken by mouth. Aprocitentan is a receptor antagonist that targets both endothelin A and endothelin B receptors. Aprocitentan was approved for medical use in the United States in March 2024. It is the first endothelin receptor antagonist to be approved by the US Food and Drug Administration (FDA) to treat systemic hypertension. The FDA considers it to be a first-in-class medication.
Article summary
Aprocitentan, sold under the brand name Tryvio, is a medication used to treat hypertension (high blood pressure). It is developed by Idorsia. It is taken by mouth. Aprocitentan is a receptor antagonist that targets both endothelin A and endothelin B receptors. Aprocitentan was approved for medical use in the United States in March 2024. It is the first endothelin receptor antagonist to be approved by the US Food and Drug Administration (FDA) to treat systemic hypertension. The FDA considers it to be a first-in-class medication.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.